title: Mechanisms of leukocyte trafficking into the CNS.
abstract: HIV-1 encephalitis occurs in up to one-third of HIV-1-infected individuals. The mechanisms through which this pathology develops are thought to involve viral passage across the blood-brain barrier (BBB), as well as entry of HIV-infected and/or uninfected inflammatory cells into the central nervous system (CNS). Viral proteins and cytokines may also contribute to the pathogenesis of encephalitis. We show that the chemokines SDF-1 and MCP-1 induce transmigration of uninfected human lymphocytes and monocytes across our model of the BBB, a co-culture of human fetal astrocytes and endothelial cells. We also demonstrate that the HIV-1 protein Tat induces adhesion molecule expression and chemokine production by human fetal astrocytes and microglia, which could further contribute to leukocyte entry into the CNS. Finally, our data indicate that inflammatory cytokines modulate the expression of CXCR4, a co-receptor for HIV-1, on human fetal astrocytes, suggesting that these cytokines may potentially modulate the infectability of astrocytes by HIV-1. These findings support the hypothesis that there may be several different mechanisms that contribute to the development and progression of HIV-1 encephalitis.
authors.affiliation: Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA.
authors.forename: D T
authors.initials: DT
authors.lastname: Wu
authors.forename: S E
authors.initials: SE
authors.lastname: Woodman
authors.forename: J M
authors.initials: JM
authors.lastname: Weiss
authors.forename: C M
authors.initials: CM
authors.lastname: McManus
authors.forename: T G
authors.initials: TG
authors.lastname: D'Aversa
authors.forename: J
authors.initials: J
authors.lastname: Hesselgesser
authors.forename: E O
authors.initials: EO
authors.lastname: Major
authors.forename: A
authors.initials: A
authors.lastname: Nath
authors.forename: J W
authors.initials: JW
authors.lastname: Berman
mesh_terms: D000328:Adult; D001253:Astrocytes / Q000378:metabolism; D001812:Blood-Brain Barrier; D001921:Brain / Q000473:pathology / Q000821:virology*; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000378:metabolism; D054377:Chemokine CXCL12; D019743:Chemokines, CXC / Q000378:metabolism; D002634:Chemotaxis, Leukocyte; D018920:Coculture Techniques; D004730:Endothelium, Vascular / Q000166:cytology; D005333:Fetus; D015696:Gene Products, tat / Q000378:metabolism; D015497:HIV-1 / Q000378:metabolism* / Q000472:pathogenicity; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D008214:Lymphocytes / Q000378:metabolism*; D009000:Monocytes / Q000378:metabolism*; D019718:Receptors, CXCR4 / Q000378:metabolism; D019010:Vascular Cell Adhesion Molecule-1 / Q000378:metabolism; D054322:tat Gene Products, Human Immunodeficiency Virus
chemical_list: C515255:CXCL12 protein, human; D018932:Chemokine CCL2; D054377:Chemokine CXCL12; D019743:Chemokines, CXC; D015696:Gene Products, tat; D019718:Receptors, CXCR4; D019010:Vascular Cell Adhesion Molecule-1; D054322:tat Gene Products, Human Immunodeficiency Virus; D018799:Intercellular Adhesion Molecule-1